A Phase I double-blind randomized single-dose two period crossover euglycemic clamp study to demonstrate equivalence in the PK and PD properties of BioGenomics Insulin Aspart and NovoRapid and to assess safety and tolerability in healthy male subjects

Trial Profile

A Phase I double-blind randomized single-dose two period crossover euglycemic clamp study to demonstrate equivalence in the PK and PD properties of BioGenomics Insulin Aspart and NovoRapid and to assess safety and tolerability in healthy male subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 12 Apr 2017

At a glance

  • Drugs Insulin aspart (Primary)
  • Indications Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Biogenomics
  • Most Recent Events

    • 30 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top